Compare Adaptive Biotechnologies Corp (ADPT) vs Allegion PLC (ALLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Allegion PLC — how do they compare? Adaptive Biotechnologies Corp trades at $24.92 (market cap $4.04B), while Allegion PLC trades at $166.39 (market cap $14.32B). The key difference: Allegion PLC is far larger — about 3.5× Adaptive Biotechnologies Corp's market cap, and Allegion PLC pays a 1.26% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | ALLE | |
|---|---|---|
Market Cap | $4.04B | $14.32B |
Sector | Health | Industrials |
52-Week High | $25.45 | $179.77 |
52-Week Low | $12.30 | $125.65 |
Enterprise Value | $4.10B | $16.03B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
ALLE trades at $165.9, up 0.22% today, near its consensus price target of $156. The stock shows bullish technical signals with strong moving average support, though RSI levels indicate potential overbought conditions. Fundamentally, the company reported robust Q2 2026 results with EPS of $2.40 beating estimates, driven by 13% revenue growth and margin expansion in the Americas segment. Recent news highlights raised full-year guidance and institutional buying interest.
Outlook remains positive given earnings momentum and raised guidance, but risks include reliance on Americas growth and cost pressures. Analyst sentiment is mixed with a Hold consensus, yet the stock's current price above the target suggests limited near-term upside. Execution on international growth and margin sustainability are key for further appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →
